A dermatologist guide to immunogenicity
Copyright policy )A dermatologist guide to immunogenicity
Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.
- Hackensack University Medical Center United States
- University of California System United States
- Palo Alto Medical Foundation United States
- University of California, San Francisco United States
- Good Samaritan Regional Medical Center United States
autoantibodies, RL1-803, HACA antibodies, antidrug antibodies, resistance to biologics, Dermatology, Article, biologic fatigue
autoantibodies, RL1-803, HACA antibodies, antidrug antibodies, resistance to biologics, Dermatology, Article, biologic fatigue
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).4 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!